Methotrexate vs alternative disease‐modifying antirheumatic drugs
Pain · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
37 questions · 38 findings · 3 reviews · Headline outcomes only
No studies found 13 · 34.2%GRADE not reported 0 · 0%Very low 3 · 7.9%Low 22 · 57.9%Moderate 0 · 0%High 0 · 0%
Methotrexate vs alternative disease‐modifying antirheumatic drugs
Global well‐being: rated by participants · children and young people with JIA
1 finding from 1 review
- no estimate extracted1 study · 94 participantsLow
Methotrexate vs alternative disease‐modifying antirheumatic drugs
Serious adverse events(4 months) · children and young people with JIA
Methotrexate showed no clear difference in serious adverse events(4 months) compared with alternative disease‐modifying antirheumatic drugs (low certainty).
1 finding from 1 review
- RR 0.14 [0.01, 2.69]1 study · 94 participantsLow
Methotrexate vs alternative disease‐modifying antirheumatic drugs
Withdrawals due to adverse events · children and young people with JIA
Methotrexate showed no clear difference in withdrawals due to adverse events(4 months) compared with alternative disease‐modifying antirheumatic drugs (low certainty).
1 finding from 1 review
- RR 0.33 [0.04, 3.09]1 study · 94 participantsLow
Methotrexate vs placebo
Sustained clinically inactive diseasec · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Methotrexate vs placebo
Function · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Methotrexate vs placebo
Pain on motion · children and young people with JIA
1 finding from 1 review
- no estimate extracted1 study · 114 participantsLow
Methotrexate vs placebo
Global well‐being: rated by participants · children and young people with JIA
Methotrexate showed no clear difference in participant global assessment of well‐being(up to 6 months) compared with placebo (low certainty).
1 finding from 1 review
- RR 1.23 [0.88, 1.72]1 study · 176 participantsLow
Methotrexate vs placebo
Serious adverse events(up to 6 months) · children and young people with JIA
Methotrexate showed no clear difference in serious adverse events(up to 6 months) compared with placebo (low certainty).
1 finding from 1 review
- RR 0.63 [0.04, 8.97]3 studies · 328 participantsLow
Methotrexate vs placebo
Withdrawals due to adverse events · children and young people with JIA
Methotrexate showed no clear difference in withdrawals due to adverse events (up to 6 months) compared with placebo (low certainty).
1 finding from 1 review
- RR 3.46 [0.6, 19.79]3 studies · 328 participantsLow
Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone
OutcomesTime frame of absolute effects · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Intervention not reported
Proportion of participants with success, defined as 0 to trace cells or 2‐step decrease in activity SUN‐grading ( · Participants with a diagnosis of JIA and uveitis who are aged 2 to 18 years old
The intervention showed no clear difference in proportion of participants with success, defined as 0 to trace cells… (low certainty).
1 finding from 1 review
- Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis‐associated uveitis 2022 · Cochrane Headline outcomes onlyRR 0.66 [0.21, 2.1]2 studies · 43 participantsLow
Intervention not reported
Risk of failure defined as 2‐step increase in activity in SUN grading ( · Participants with a diagnosis of JIA and uveitis who are aged 2 to 18 years old
The intervention showed no clear difference in risk of failure defined as 2‐step increase in activity in SUN… (low certainty).
1 finding from 1 review
- Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis‐associated uveitis 2022 · Cochrane Headline outcomes onlyRR 0.31 [0.01, 7.15]1 study · 31 participantsLow
Intervention not reported
Risk of recurrence and mean time‐to‐recurrence after induction of remission at 2 or 6 months · Participants with a diagnosis of JIA and uveitis who are aged 2 to 18 years old
1 finding from 1 review
- Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis‐associated uveitis 2022 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedVery low
Intervention not reported
Mean change from baseline in logMAR visual acuity at 6 months*2 · Participants with a diagnosis of JIA and uveitis who are aged 2 to 18 years old
1 finding from 1 review
- Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis‐associated uveitis 2022 · Cochrane Headline outcomes onlyno estimate extracted1 study · 90 participantsLow
Intervention not reported
Mean change from baseline in number of topical or systemic steroids at 6 months*2 · Participants with a diagnosis of JIA and uveitis who are aged 2 to 18 years old
1 finding from 1 review
- Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis‐associated uveitis 2022 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedLow
Intervention not reported
Frequency and nature of adverse effects · Participants with a diagnosis of JIA and uveitis who are aged 2 to 18 years old
1 finding from 1 review
- Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis‐associated uveitis 2022 · Cochrane Headline outcomes onlyno estimate extracted3 studies · 134 participantsLow